GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

A recent study reveals that weight tends to be regained after discontinuing anti-obesity medications (AOMs) such as Ozempic, despite initial successful weight loss.

A TikTokker posting under the name @JonBoy_LosesIt has shared his attitude to the loose skin he's been left with after losing ...

It would work, for a while, and she would lose some weight. Ultimately, however, “I couldn’t get over the obsession with food ...

A woman is speaking out after her successful attempt to buy weight-loss drug Mounjaro by using a ‘before’ image of another ...

Roughly one in three preteens and teens ages 12 to 17 in the United States had prediabetes in 2023, according to new data ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.